The quest for ligands and binding partners of atypical cadherin FAT1

A recent study in Scientific Reports identified glypican-3 (GPC3) as a novel extracellular interacting protein for FAT1 in hepato-cellular carcinoma (HCC) cells. FAT1 is a large transmembrane atypical cadherin with limited knowledge existing about its binding partners. While in Drosophila, dachsous (ds), another transmembrane member of the cadherin superfamily, is known to function as FAT1 ligand, no ligand is known in mammals so far. The revelation of GPC3 as a potential binding partner of FAT1 extracellular domain unfolds an opportunity to study potential triggers of FAT1 signaling in cancers. Available inhibitors of GPC3 in various phases of clinical trials also present an attractive option to curb GPC3-FAT1 signaling in tumors that overexpress these proteins.

Automated summary

A recent study identified GPC3 as a potential binding partner of FAT1 in HCC cells, providing an opportunity to study potential triggers of FAT1 signaling in cancers. Inhibitors of GPC3 currently in clinical trials offer an attractive option to curb GPC3-FAT1 signaling in tumors that overexpress these proteins.